Icrucumab
Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.
Snapshot
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors. Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1324163146 under CC BY-SA 4.0; modifications have been made.